Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
(Reuters) - A pair of newer drugs proved no better, and by some measures inferior, to the older and cheaper chemotherapy agent paclitaxel in patients with locally advanced or metastatic breast cancer, according to results of a late stage study.
(Reuters) - Interim results from a mid-stage trial of Celldex Therapeutics Inc's experimental drug showed trends toward reducing tumors in patients with advanced breast cancer, with rates improving for those patients with high levels of a key protein.
Learn how new research has prompted the American Society of Clinical Onclolgy (ASCO) to recommend that doctors offer palliative care alongside standard medical treatment for people diagnosed with metastatic cancers.
(Reuters) - AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.
Learn how the combination of everolimus and the hormonal therapy exemestane may offer a new treatment option for postmenopausal women with locally advanced or metastatic estrogen-receptor positive, HER2-negative breast cancer.
Learn how the experiemental medicine pertuzumab improves progression-free survival and may offer a new treatment option for women with metastatic HER2 positive breast cancer.
WASHINGTON (Reuters) - U.S. drug regulators on Friday withdrew approval of Roche's Avastin as a treatment for breast cancer, capping a protracted and emotional battle over a drug backed by many survivors of the disease.
NEW YORK (Reuters Health) - An international survey of cancer doctors shows many question U.S. health advisers' 2010 rejection of Roche's drug Avastin to treat advanced breast cancer.
(Reuters) - Health insurer Blue Shield of California has decided not to pay for Roche Holding's drug Avastin to treat breast cancer after health advisers said it was not safe or clinically beneficial.